eligibility_summary
Eligible: adults 18–70, ECOG 0–2, pathologic breast cancer needing radiotherapy to chest wall/breast ± nodes, and planned guideline-based systemic therapy with capecitabine, a CDK4/6 inhibitor, PARP inhibitor, immune checkpoint inhibitor, or HER2 inhibitor. Exclude: male patients, allergy to listed drugs, trastuzumab monotherapy during/after RT, severe comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06197581: Prospective safety study of concurrent chest wall/breast ± nodal radiotherapy with systemic therapy in breast cancer. Interventions and mechanisms: Capecitabine (oral antimetabolite prodrug of 5‑FU, inhibits thymidylate synthase, radiosensitizer). HER2 inhibitors—trastuzumab (mAb to HER2/ERBB2), pertuzumab (mAb blocking HER2 dimerization), T‑DM1/ado‑trastuzumab emtansine (antibody‑drug conjugate delivering microtubule toxin DM1). CDK4/6 inhibitors—abemaciclib, palbociclib, ribociclib (small‑molecule kinase inhibitors, block CDK4/6→Rb phosphorylation, G1 arrest). PARP inhibitors—olaparib etc. (small molecules inhibiting PARP1/2, impair SSB repair, radiosensitizing, synthetic lethality in BRCA1/2). Immune checkpoint inhibitors—pembrolizumab/anti‑PD‑1 or anti‑PD‑L1 mAbs (restore T‑cell activity). Targets/pathways: tumor DNA damage (RT), HER2/ERBB2, CDK4/6‑Rb axis, PARP‑mediated BER/HR‑deficient cells, PD‑1/PD‑L1 on T cells/tumor cells, thymidylate synthase, microtubules.